Figure EV3. Acute and chronic FK506 treatment of WT, HTT_SA, and Mecp2 KO mice.

• A
  Western blot of HTT S421 phosphorylation. We treated WT and HTT_SA 30‐day‐old mice intraperitoneally with FK506 (5 mg/kg) or vehicle and analyzed brain extracts for endogenous HTT phosphorylation by Western blotting, 2 h after administration (WT FK506 = 3, WT Vehicle = 6, HTT_SA FK506 = 3, HTT_SA Vehicle = 3). The relative protein level of phospho‐HTT was normalized on total HTT protein level and is presented as the ratio. Data are presented as the means ± SEM, *P < 0.05, Mann–Whitney test.
• B
  Western blot of HTT S421 phosphorylation. We treated WT, HTT_SA, and Mecp2 KO 30‐day‐old mice intraperitoneally with FK506 (5 mg/kg) or vehicle chronically for 20 days and analyzed brain extracts for endogenous HTT phosphorylation by Western blotting, 2 h after the last administration (KO FK506 n = 2, KO Vehicle n = 2, WT FK506 = 2, WT Vehicle = 2, HTT_SA FK506 = 2, HTT_SA Vehicle = 2).
• C
  Western blot of HTT and Mecp2. We treated WT and Mecp2 KO 30‐day‐old mice intraperitoneally with FK506 (5 mg/kg) or vehicle chronically for 20 days (WT FK506 = 3, WT Vehicle = 3, HTT_SA FK506 = 3, HTT_SA Vehicle = 3). Data are presented as the means ± SEM, ns = not significant, Mann–Whitney test.

Source data are available online for this figure.